Evidence map›Paper›PMID 32373646›Full record

ArticleOpen forum infectious diseases2020

Standardized Urine-Based Tuberculosis (TB) Screening With TB-Lipoarabinomannan and Xpert MTB/RIF Ultra in Ugandan Adults With Advanced Human Immunodeficiency Virus Disease and Suspected Meningitis.

Fiona V Cresswell, Jayne Ellis, Enock Kagimu, Ananta S Bangdiwala, Michael Okirwoth, Gerald Mugumya, Morris Rutakingirwa, John Kasibante, Carson M Quinn, Kenneth Ssebambulidde and 11 more

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Observational
  8. Tuberculosis and HIV coinfection: Progress and challenges towards reducing incidence and mortality.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2025
    Review
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Distal jejunal obstruction due toMedical mycology case reports · 2022
    Article
  17. Diagnosing Tuberculosis: What Do New Technologies Allow Us to (Not) Do?Respiration; international review of thoracic diseases · 2022
    Review
  18. Review
  19. Article
  20. Cerebrospinal Fluid Lactate as a Prognostic Marker of Disease Severity and Mortality in Cryptococcal Meningitis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 3 countries.

Fiona V CresswellInfectious Diseases Institute, Makerere University, Kampala, Uganda.ORCID 0000-0002-5070-532X
Jayne EllisHospital for Tropical Diseases, University College London Hospitals NHS Foundation Trust, London, United Kingdom.ORCID 0000-0002-7009-9144
Enock KagimuInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Ananta S BangdiwalaDivision of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.
Michael OkirwothInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Gerald MugumyaMicrobiology Laboratory, Kiruddu Referral Hospital, Kampala, Uganda.
Morris RutakingirwaInfectious Diseases Institute, Makerere University, Kampala, Uganda.
John KasibanteInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Carson M QuinnInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Kenneth SsebambuliddeInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Joshua RheinInfectious Diseases Institute, Makerere University, Kampala, Uganda.ORCID 0000-0002-0480-9646
Edwin NuwagiraMbarara University of Science and Technology, Mbarara, Uganda.
Lillian TugumeInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Emily MartynInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Caleb P SkipperInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Conrad MuzooraMbarara University of Science and Technology, Mbarara, Uganda.
Daniel GrintTropical Epidemiology Group, London School of Hygiene and Tropical Medicine, London, United Kingdom.
David B MeyaInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Nathan C BahrDivision of Infectious Diseases, Department of Medicine, University of Kansas, Kansas City, Kansas, USA.
Alison M ElliottClinical Research Department, London School of Hygiene and Tropical Medicine, London, United Kingdom.
David R BoulwareDivision of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Infectious Diseases Institute · UGUniversity of Minnesota · USLondon School of Hygiene & Tropical Medicine · GBMbarara University of Science and Technology · UGUniversity of Kansas · USUniversity College London Hospitals NHS Foundation Trust · GB

Funding

Improving Diagnostics and Neurocognitive Outcomes in HIV/AIDS-related MeningitisR01NS086312 · NINDS · UNIVERSITY OF MINNESOTA · PI David R Boulware, David Bisagaya Meya · 2013 to 2026
$8.3M
Infectious Disease Training in Clinical InvestigationT32AI055433 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI David R Boulware · 2003 to 2026
$6.1M
Redefining Tuberculosis Meningitis with Metagenomics and Host TransciptomicsR01AI145437 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WILSON, MICHAEL R · 2019 to 2023
$3.5M
Novel Diagnostic Development for TB Meningitis and HistoplasmosisK23NS110470 · NINDS · UNIVERSITY OF MINNESOTA · PI BAHR, NATHAN · 2019 to 2023
$1.0M
Improving Outcomes of HIV-Associated Cryptococcosis in Resource-Limited SettingsK01TW010268 · FIC · UNIVERSITY OF MINNESOTA · PI RHEIN, JOSHUA R · 2016 to 2020
$703k
FIC NIH HHS K01 TW010268Medical Research Council MC_UU_00027/5Medical Research Council MR/R010161/1NIAID NIH HHS R01 AI145437NIAID NIH HHS T32 AI055433NINDS NIH HHS K23 NS110470NINDS NIH HHS R01 NS086312Wellcome Trust 107743
6 · The paper itself

Abstract

backgroundDiagnosis of extrapulmonary tuberculosis (TB) remains challenging. We sought to determine the prevalence of disseminated TB by testing urine with TB-lipoarabinomannan (TB-LAM) lateral flow assay and Xpert MTB/RIF Ultra (Ultra) in hospitalized adults.

methodsWe prospectively enrolled human immunodeficiency virus (HIV)-positive adults with suspected meningitis in Uganda during 2018-2020. Participants underwent standardized urine-based TB screening. Urine (60 mcL) was tested with TB-LAM (Alere), and remaining urine was centrifuged with the cell pellet resuspended in 2 mL of urine for Xpert Ultra testing.

resultsWe enrolled 348 HIV-positive inpatients with median CD4 of 37 cells/mcL (interquartile range, 13-102 cells/mcL). Overall, 26% (90 of 348; 95% confidence interval [CI], 21%-30%) had evidence of disseminated TB by either urine assay. Of 243 participants with both urine TB-LAM and Ultra results, 20% (48 of 243) were TB-LAM-positive, 12% (29 of 243) were Ultra-positive, and 6% (14 of 243) were positive by both assays. In definite and probable TB meningitis, 37% (14 of 38) were TB-LAM-positive and 41% (15 of 37) were Ultra-positive. In cryptococcal meningitis, 22% (40 of 183) were TB-LAM-positive and 4.4% (6 of 135) were Ultra-positive. Mortality trended higher in those with evidence of disseminated TB by either assay (odds ratio = 1.44; 95% CI, 0.83-2.49;

conclusionsIn hospitalized Ugandans with advanced HIV disease and suspected meningitis, systematic screening with urine TB-LAM and Ultra found a high prevalence of urine TB test positivity (26%). In those with TB meningitis, urine tests were positive in over one third. There was little concordance between Ultra and TB-LAM, which warrants further investigation.

Indexed as

HIVmeningitisTB-LAMtuberculosisXpert MTB/RIF Ultra

Identifiers

PMID32373646
PMCPMC7192026
OpenAlexW3013209169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.